The Food and Drug Administration has approved the first treatment shown to help children and adults with the most severe form of Niemann-Pick disease type C live longer, a milestone for families who have waited years for an option against the rare, inherited brain disease.
The drug, Lembaz (adrabetadex), was approved on Tuesday, Nov. 17, for patients whose neurological symptoms began before age 6, a group known as infantile-onset NPC. The approval went to Mandos, LLC, a subsidiary of Beren Therapeutics. Pharmaphorum reported the company expects the treatment to reach U.S. treatment sites next month.
“For the first time, there is a treatment shown to help adults and children with this serious disease live longer,” said Acting FDA Commissioner Kyle Diamantas.
What is Niemann-Pick disease type C?
Niemann-Pick disease type C, or NPC, is a rare, inherited condition that affects an estimated 1 in 150,000 people, according to the FDA. The body cannot properly move and process cholesterol and other fats inside cells, so they build up, mainly in the brain. Over time, the disease takes away movement, coordination and the ability to swallow.
It is passed down when a child inherits a faulty copy of a gene, most often NPC1, from both parents, according to Contemporary Pediatrics. Patients whose symptoms start in early childhood have the most serious form. The FDA estimates only a few hundred people in the U.S. have the disease, Pharmaphorum reported.
What the FDA approved
- Who it is for: Adults and children who weigh at least 7 kilograms (about 15 pounds) and whose neurological symptoms began before age 6.
- How it is given: A trained health care provider injects it directly into the spinal canal (an intrathecal injection) every two weeks.
- How it works: Lembaz is a cyclodextrin-based drug. Beren says it is the first FDA-approved medicine to target the underlying cholesterol-trafficking problem in NPC.
- Cost: A list price had not been announced, according to Pharmaphorum.
What the evidence showed
The FDA reviewed survival data from 36 patients with infantile-onset NPC who were treated across three clinical studies and an expanded access program. Compared with a matched outside control group, treated patients had a 55% lower risk of death. Median survival was 8.5 years for patients on Lembaz, compared with 4.9 years for the comparison group. The benefit appeared whether or not patients also took miglustat, an older drug often used off-label for NPC.
One caution: the comparison group was an external, matched group, not patients randomly assigned in the same trial, so the results are not from a standard randomized study.
Two other NPC drugs, Miplyffa and Aqneursa, were approved earlier, but the FDA says neither has been shown to reduce the risk of death, and both have age and weight limits.
Side effects and a boxed warning
Lembaz carries a boxed warning, the FDA’s strongest, for hearing impairment, including permanent hearing loss. The agency says patients should have a full hearing evaluation before starting and regularly during treatment, and doses may need adjusting based on the results. Other common side effects include balance and coordination problems, fatigue, vomiting, back pain, headache, fever, diarrhea, nausea and cough.
A long road for families
The approval came on the FDA’s target date after a review extended by three months earlier this year, Contemporary Pediatrics reported. Beren CEO Jason Camm told Pharmaphorum the approval reflects “nearly two decades of determination” from families, caregivers, clinicians, researchers and advocates.
It is the latest in a run of notable FDA decisions, including the recent approval of a first-of-its-kind drug to prevent a second event, and it comes in a week when public health news has been dominated by the loss of U.S. measles elimination status.
Why it matters for families
Rare diseases are individually uncommon, but for the families who face them, a new approved option can change what the future looks like. For parents of a child with infantile-onset NPC, this approval means a treatment with survival data behind it, rather than only drugs aimed at symptoms.
- Early signs of NPC can vary. If you have concerns about a child’s coordination, movement, swallowing or development, talk with your pediatrician.
- Families already living with NPC should talk with their child’s specialist about whether Lembaz is an option, what hearing monitoring involves, and when it will be available at their treatment center.
- Patient groups such as the National Niemann Pick Disease Foundation can help families connect with resources and other families.
This article is general information, not medical advice. Decisions about treatment should be made with a doctor.
What to watch next
Watch for the drug’s price, insurance coverage decisions, and how quickly treatment centers begin offering it after the expected December launch. Upstormed News will follow the rollout.
Read more: Wegovy Cut BMI 13.5% in Children 6-11
What do you think this approval means for families facing rare diseases? Tell us in the comments.
Sources: U.S. Food and Drug Administration, “FDA Approves First Drug Shown to Help Patients with Infantile-Onset Niemann-Pick Disease Type C Live Longer” (November 17, 2026); Pharmaphorum, “Beren’s Niemann-Pick drug Lembaz cleared by FDA” (November 18, 2026); RTTNews, “FDA Approves First Therapy Shown To Extend Survival In Infantile-Onset Niemann-Pick Disease Type C” (November 18, 2026); Contemporary Pediatrics, “FDA extends adrabetadex NDA review for infantile-onset Niemann-Pick disease type C” (May 28, 2026)





Leave a Reply